Drug Profile
Research programme: Zika virus infection vaccine - CaroGen Corporation
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator CaroGen
- Developer CaroGen; University of Connecticut
- Class Synthetic vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Zika virus infection
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA
- 03 Aug 2016 Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route)